No1258: A multicenter, open-label, four-arm, randomized trial, evaluating the safety and tolerability of BRIVARACETAM intravenous infusion and bolus, administered in b.i.d. regimen as an adjunctive antiepileptic treatment in subject from 16 to 70 years su

Grants and Contracts Details

StatusFinished
Effective start/end date10/21/11 → 3/31/14

Funding

  • UCB Pharma (domestic): $41,084.00